+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06534060

Phase 2 Study of MB-105, a CAR T-cell Therapy, for Adults With CD5 Positive Relapsed or Refractory T-cell Lymphoma

Led by March Biosciences Inc · Updated on 2025-10-03

46

Participants Needed

12

Research Sites

95 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MB-105, a CAR T-cell therapy, in patients with CD5 Positive RelapsedRefractory T-cell Lymphoma rr TCL. This Phase 2, open-label, multicenter study uses a Simon two-stage design to assess the safety and preliminary effectiveness of MB-105 in this specific lymphoma population. The study aims to better understand the response rates and safety profile of this investigational treatment. The study is divided into two stages. The first stage will enroll about 15 patients, starting with a safety run-in of 6 patients receiving a fixed dose of 50 million CAR-positive cells. An Independent Data Monitoring Committee IDMC will review safety data before continuing. If the dose is confirmed appropriate, 9 more patients will be enrolled to complete Stage 1. Stage 2 will then enroll approximately 31 additional patients, with ongoing safety and efficacy monitoring every 6 months. The study treatment consists of autologous T-cells engineered to express the CD5 CAR, delivered as MB-105. Participants will undergo screening, dosing, and follow-up visits up to at least 12 months after treatment. Assessments include monitoring adverse events, measuring tumor response using Lugano and Global criteria, and evaluating survival outcomes. Safety monitoring continues throughout the study, with long-term follow-up offered after study completion. The total participation duration includes treatment, up to one year of follow-up, and optional extended long-term monitoring.

CONDITIONS

Brief Title

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Research Team

F

Federica Giordano, Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here